All In Biotech

Drug Trial Radar · NCT04856085

Study of VIR-2218, VIR-3434, and/or PEG-IFNα in Subjects With Chronic Hepatitis B Virus Infection

A Phase 2 Study to Evaluate the Safety, Tolerability, and Efficacy of Regimens Containing VIR-2218, VIR-3434, and/or PEG-IFNα in Subjects With Chronic Hepatitis B Virus Infection

Last checked: Nov 19, 2026Latest source record: Apr 23, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

244

Actual

Start

Jul 11, 2021

Primary completion

Mar 16, 2026

Study completion Mar 16, 2026

Sponsor

Lead sponsor
Vir Biotechnology, Inc.Industry
Sponsor type
Industry
First posted
Apr 22, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a phase 2 study in which participants with chronic hepatitis B virus (HBV) infection will receive VIR-2218, VIR-3434 and/or PEG-IFNα and be assessed for safety, tolerability, and efficacy

Conditions

  • Hepatitis B, Chronic

Interventions

  • VIR-2218Drug

    VIR-2218 given by subcutaneous injection

  • VIR-3434Drug

    VIR-3434 given by subcutaneous injection

  • PEG-IFNαDrug

    PEG-IFNα given by subcutaneous injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Proportion of participants with treatment-emergent adverse events (TEAEs)Time frame: Up to 72 weeks
  2. Proportion of participants with serious adverse events (SAEs)Time frame: Up to 72 weeks
  3. Proportion of participants with hepatitis B surface antigen (HBsAg) loss (defined as undetectable HBsAg) at end of treatmentTime frame: Up to 48 weeks
  4. Proportion of participants with HBsAg loss (defined as undetectable HBsAg) at 24 weeks post-end of treatmentTime frame: Up to 72 weeks

Locations

37 sites in 12 countries. Site status is shown where the registry gives one.

  • Investigative Site

    San Francisco, California

  • Investigative Site

    Miami, Florida

  • Investigative Site

    Orlando, Florida

  • Investigative Site

    Baltimore, Maryland

  • Investigative Site

    Hillsborough, New Jersey

  • Investigative Site

    Toronto, Canada

  • Investigative Site

    Toronto, Canada

  • Investigative Site

    Vancouver, Canada

  • Investigative Site

    Frankfurt, Germany

  • Investigative Site

    Hanover, Germany

  • Investigative Site

    Mannheim, Germany

  • Investigative Site

    Hong Kong, Hong Kong

  • Investigative Site

    Hong Kong, Shatin, Hong Kong

  • Investigative Site

    Hong Kong, Tai Po District, Hong Kong

  • Investigative Site

    Kuala Lumpur, Malaysia

  • Investigative Site

    Chisinau, Moldova

  • Investigative Site

    Auckland, New Zealand

  • Investigative Site

    Auckland, New Zealand

  • Investigative Site

    Hamilton, New Zealand

  • Investigative Site

    Tauranga, New Zealand

  • Investigative Site

    Wellington, New Zealand

  • Investigative Site

    Bucharest, Romania

  • Investigative Site

    Busan, South Korea

  • Investigative Site

    Seoul, South Korea

  • Investigative Site

    Seoul, South Korea

  • Investigative Site

    Yangsan, South Korea

  • Investigative Site

    Chiayi City, Taiwan

  • Investigative Site

    Kaohsiung City, Taiwan

  • Investigative Site

    Kaohsiung City, Taiwan

  • Investigative Site

    Taichung, Taiwan

  • Investigative Site

    Taipei, Taiwan

  • Investigative Site

    Taoyuan City, Taiwan

  • Investigative Site

    Kyiv, Ukraine

  • Investigative Site

    Birmingham, United Kingdom

  • Investigative Site

    London, United Kingdom

  • Investigative Site

    London, United Kingdom

  • Investigative Site

    Manchester, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.